Investment analysts at Chardan Capital initiated coverage on shares of Outlook Therapeutics (NASDAQ:OTLK – Get Rating) in a note issued to investors on Tuesday, September 13th, MarketBeat.com reports. The firm set a “buy” rating on the stock.
Separately, Ascendiant Capital Markets decreased their price objective on Outlook Therapeutics to $7.00 in a research report on Monday, August 22nd.
Outlook Therapeutics Stock Performance
Shares of OTLK traded down $0.02 during midday trading on Tuesday, hitting $1.24. The stock had a trading volume of 598,807 shares, compared to its average volume of 1,042,930. The business has a 50-day simple moving average of $1.16 and a two-hundred day simple moving average of $1.39. Outlook Therapeutics has a fifty-two week low of $0.68 and a fifty-two week high of $2.40.
Hedge Funds Weigh In On Outlook Therapeutics
Hedge funds have recently modified their holdings of the stock. ProShare Advisors LLC grew its stake in Outlook Therapeutics by 70.5% in the fourth quarter. ProShare Advisors LLC now owns 19,461 shares of the company’s stock valued at $26,000 after purchasing an additional 8,050 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in Outlook Therapeutics by 174.2% in the second quarter. BNP Paribas Arbitrage SA now owns 25,837 shares of the company’s stock worth $26,000 after buying an additional 16,414 shares during the last quarter. Flower City Capital acquired a new stake in Outlook Therapeutics in the first quarter valued at approximately $36,000. Envestnet Asset Management Inc. bought a new stake in Outlook Therapeutics in the fourth quarter worth approximately $50,000. Finally, Principal Financial Group Inc. increased its stake in shares of Outlook Therapeutics by 92.8% during the 4th quarter. Principal Financial Group Inc. now owns 36,686 shares of the company’s stock worth $50,000 after purchasing an additional 17,661 shares during the last quarter. 11.71% of the stock is owned by institutional investors and hedge funds.
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
- Get a free copy of the StockNews.com research report on Outlook Therapeutics (OTLK)
- Has AMD stock stock fallen too far?
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.